CL2014000783A1 - Metodos para determinar si se necesita usar un farmaco depurador de nitrogeno o para determinar el incremento de una dosificacion del farmaco depurador de nitrogeno en un sujeto que recibe actualmente dicho farmaco; y uso del farmaco depurador de nitrogeno para el tratamiento de un trastorno de retencion de nitrogeno, tal como un trastorno del ciclo de urea y encefalopatia hepatica. - Google Patents
Metodos para determinar si se necesita usar un farmaco depurador de nitrogeno o para determinar el incremento de una dosificacion del farmaco depurador de nitrogeno en un sujeto que recibe actualmente dicho farmaco; y uso del farmaco depurador de nitrogeno para el tratamiento de un trastorno de retencion de nitrogeno, tal como un trastorno del ciclo de urea y encefalopatia hepatica.Info
- Publication number
- CL2014000783A1 CL2014000783A1 CL2014000783A CL2014000783A CL2014000783A1 CL 2014000783 A1 CL2014000783 A1 CL 2014000783A1 CL 2014000783 A CL2014000783 A CL 2014000783A CL 2014000783 A CL2014000783 A CL 2014000783A CL 2014000783 A1 CL2014000783 A1 CL 2014000783A1
- Authority
- CL
- Chile
- Prior art keywords
- drug
- nitrogen
- disorder
- dosage
- purification
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 8
- 239000003814 drug Substances 0.000 title 4
- 229940079593 drug Drugs 0.000 title 4
- 229910052757 nitrogen Inorganic materials 0.000 title 4
- 238000000746 purification Methods 0.000 title 2
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000007386 hepatic encephalopathy Diseases 0.000 title 1
- 230000014759 maintenance of location Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 208000030954 urea cycle disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
- G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
- G01N31/221—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators for investigating pH value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
- Y10T436/173845—Amine and quaternary ammonium
- Y10T436/175383—Ammonia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Ecology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542100P | 2011-09-30 | 2011-09-30 | |
| US201161564668P | 2011-11-29 | 2011-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000783A1 true CL2014000783A1 (es) | 2015-01-16 |
Family
ID=47892277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000783A CL2014000783A1 (es) | 2011-09-30 | 2014-03-28 | Metodos para determinar si se necesita usar un farmaco depurador de nitrogeno o para determinar el incremento de una dosificacion del farmaco depurador de nitrogeno en un sujeto que recibe actualmente dicho farmaco; y uso del farmaco depurador de nitrogeno para el tratamiento de un trastorno de retencion de nitrogeno, tal como un trastorno del ciclo de urea y encefalopatia hepatica. |
Country Status (25)
| Country | Link |
|---|---|
| US (21) | US8404215B1 (enExample) |
| EP (2) | EP2760479B1 (enExample) |
| JP (2) | JP6073898B2 (enExample) |
| KR (2) | KR102019000B1 (enExample) |
| CN (2) | CN104039358A (enExample) |
| AU (2) | AU2012316750B2 (enExample) |
| BR (1) | BR112014007357B1 (enExample) |
| CA (1) | CA2850391A1 (enExample) |
| CL (1) | CL2014000783A1 (enExample) |
| CY (1) | CY1119028T1 (enExample) |
| DK (1) | DK2760479T3 (enExample) |
| ES (1) | ES2629859T3 (enExample) |
| HR (1) | HRP20171063T1 (enExample) |
| HU (1) | HUE035220T2 (enExample) |
| IL (2) | IL231732A (enExample) |
| LT (1) | LT2760479T (enExample) |
| MX (2) | MX366197B (enExample) |
| PL (1) | PL2760479T3 (enExample) |
| PT (1) | PT2760479T (enExample) |
| RS (1) | RS56196B1 (enExample) |
| SG (1) | SG11201400781TA (enExample) |
| SI (1) | SI2760479T1 (enExample) |
| SM (1) | SMT201700321T1 (enExample) |
| WO (1) | WO2013048558A2 (enExample) |
| ZA (1) | ZA201401851B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2760479T3 (pl) | 2011-09-30 | 2017-09-29 | Horizon Therapeutics, Llc | Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu |
| CN111991383A (zh) * | 2012-04-20 | 2020-11-27 | 伊梅尔迪卡制药公司 | 苯乙酸前药的治疗性监测方法 |
| LT2922576T (lt) * | 2012-11-21 | 2018-02-12 | Horizon Therapeutics, Llc | Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai |
| US20150094278A1 (en) * | 2013-09-30 | 2015-04-02 | Hyperion Therapeutics, Inc. | Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy |
| PT2986325T (pt) * | 2013-10-14 | 2019-10-09 | Immedica Pharma Ab | Métodos para tratar distúrbios do ciclo da ureia |
| EP3782610A1 (en) | 2013-11-14 | 2021-02-24 | Ultragenyx Pharmaceutical Inc. | Solid compositions of triglycerides and uses tehreof |
| ES2861594T3 (es) | 2014-04-30 | 2021-10-06 | Univ Johns Hopkins | Composiciones de dendrímeros y su uso en el tratamiento de enfermedades del ojo |
| WO2015187641A1 (en) * | 2014-06-04 | 2015-12-10 | Horizon Therapeutics, Inc. | Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels |
| AU2015301575B2 (en) | 2014-08-13 | 2018-05-10 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| JP7088473B2 (ja) | 2015-10-29 | 2022-06-21 | ザ・ジョンズ・ホプキンス・ユニバーシティー | ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法 |
| WO2017147193A1 (en) * | 2016-02-22 | 2017-08-31 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| JP6752748B2 (ja) | 2017-03-30 | 2020-09-09 | 住友重機械工業株式会社 | 減速装置 |
| JP7454945B2 (ja) * | 2017-07-03 | 2024-03-25 | アボット・ラボラトリーズ | 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法 |
| MX2020002057A (es) * | 2017-08-22 | 2020-07-13 | Regeneron Pharma | Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon. |
| US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
| JP7759322B2 (ja) | 2019-12-04 | 2025-10-23 | アシュバッタ セラピューティクス， インコーポレイテッド | 眼に薬物送達するためのデンドリマー組成物および方法 |
| WO2022011061A1 (en) * | 2020-07-07 | 2022-01-13 | Acer Therapeutics Inc. | Methods of administering taste masked phenylbutyrate and compositions therefor |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1004595A (en) | 1911-05-25 | 1911-10-03 | Sargents Sons Corp C G | Carrier for washing-bowls. |
| US1018300A (en) | 1911-06-12 | 1912-02-20 | John Davidson | Condensing steam-engine. |
| US3686238A (en) | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| US5879657A (en) | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| CA2212047C (en) | 1995-02-07 | 2010-11-16 | Saul W. Brusilow | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders |
| DE19805854C1 (de) | 1998-02-13 | 1999-05-12 | Claas Usines France | Schalteinrichtung für Schneidmesser |
| US6219567B1 (en) * | 1999-06-21 | 2001-04-17 | Cardiox Corporation | Monitoring of total ammoniacal concentration in blood |
| IT1317073B1 (it) | 2000-12-12 | 2003-05-26 | Mini Ricerca Scient Tecnolog | Esteri dell'acido fenilbutirrico, procedimenti per la loro produzionee loro impiego terapeutico. |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US6825384B1 (en) | 2004-01-29 | 2004-11-30 | The Nutrasweet Company | Bromine free TEMPO based catalyst system for oxidation of primary and secondary alcohols using NaOCl as an oxidant |
| US20050273359A1 (en) | 2004-06-03 | 2005-12-08 | Young David E | System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure |
| CN1778963A (zh) * | 2004-11-23 | 2006-05-31 | 苏州艾杰生物科技有限公司 | 血氨含量测定方法及血氨诊断试剂盒 |
| WO2006056794A1 (en) * | 2004-11-26 | 2006-06-01 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| US20070004805A1 (en) | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
| US20100016207A1 (en) | 2005-11-10 | 2010-01-21 | Wurtman Richard J | Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid |
| US8094521B2 (en) | 2007-02-28 | 2012-01-10 | Nightingale Products LLC | Caregiver personal alert device |
| US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| PL3133396T3 (pl) | 2008-04-29 | 2019-03-29 | Horizon Therapeutics, Llc | Sposób leczenia z zastosowaniem leków wychwytujących amoniak |
| WO2009145323A1 (ja) | 2008-05-30 | 2009-12-03 | 日産化学工業株式会社 | 多環式化合物を用いるアルコールの酸化方法 |
| ES2593378T3 (es) | 2008-08-29 | 2016-12-09 | Horizon Therapeutics, Llc | Métodos de tratamiento usando fármacos de secuestro de ammonia |
| WO2010025303A1 (en) | 2008-08-29 | 2010-03-04 | Hyperion Therapeutics | Dosing and monitoring patients on nitrogen-scavenging drugs |
| EP2456304B1 (en) | 2009-07-24 | 2015-08-19 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| EP2594550B1 (en) | 2010-07-16 | 2016-10-12 | Tohoku University | Method for oxidizing alcohols |
| US20130224277A1 (en) | 2010-08-31 | 2013-08-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation |
| PL2760479T3 (pl) | 2011-09-30 | 2017-09-29 | Horizon Therapeutics, Llc | Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu |
| EP2607366A1 (en) | 2011-12-21 | 2013-06-26 | Lunamed AG | Glycerol phenyl butyrate esters |
| CN111991383A (zh) | 2012-04-20 | 2020-11-27 | 伊梅尔迪卡制药公司 | 苯乙酸前药的治疗性监测方法 |
| LT2922576T (lt) | 2012-11-21 | 2018-02-12 | Horizon Therapeutics, Llc | Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai |
| CN103304402B (zh) | 2013-05-24 | 2015-04-22 | 苏州诚和医药化学有限公司 | 一种制备4-苯-1-丁酸的方法 |
| US20150094278A1 (en) | 2013-09-30 | 2015-04-02 | Hyperion Therapeutics, Inc. | Methods of diagnosing, grading, monitoring, and treating hepatic encephalopathy |
| PT2986325T (pt) | 2013-10-14 | 2019-10-09 | Immedica Pharma Ab | Métodos para tratar distúrbios do ciclo da ureia |
| WO2015063659A1 (en) | 2013-10-30 | 2015-05-07 | Lupin Limited | Process for the preparation of glycerol phenylbutyrate |
| WO2015187641A1 (en) | 2014-06-04 | 2015-12-10 | Horizon Therapeutics, Inc. | Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels |
| WO2017147193A1 (en) | 2016-02-22 | 2017-08-31 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US20190076383A1 (en) | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
| US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
-
2012
- 2012-03-09 PL PL12835407T patent/PL2760479T3/pl unknown
- 2012-03-09 JP JP2014533519A patent/JP6073898B2/ja active Active
- 2012-03-09 BR BR112014007357-0A patent/BR112014007357B1/pt active IP Right Grant
- 2012-03-09 KR KR1020187020761A patent/KR102019000B1/ko active Active
- 2012-03-09 EP EP12835407.3A patent/EP2760479B1/en active Active
- 2012-03-09 EP EP17168773.4A patent/EP3263102A1/en not_active Withdrawn
- 2012-03-09 ES ES12835407.3T patent/ES2629859T3/es active Active
- 2012-03-09 SG SG11201400781TA patent/SG11201400781TA/en unknown
- 2012-03-09 LT LTEP12835407.3T patent/LT2760479T/lt unknown
- 2012-03-09 DK DK12835407.3T patent/DK2760479T3/en active
- 2012-03-09 MX MX2014003854A patent/MX366197B/es active IP Right Grant
- 2012-03-09 SM SM20170321T patent/SMT201700321T1/it unknown
- 2012-03-09 CA CA2850391A patent/CA2850391A1/en not_active Withdrawn
- 2012-03-09 HU HUE12835407A patent/HUE035220T2/hu unknown
- 2012-03-09 AU AU2012316750A patent/AU2012316750B2/en active Active
- 2012-03-09 CN CN201280048373.5A patent/CN104039358A/zh active Pending
- 2012-03-09 KR KR1020147011146A patent/KR20140094517A/ko not_active Ceased
- 2012-03-09 US US13/417,137 patent/US8404215B1/en active Active
- 2012-03-09 CN CN201710239760.1A patent/CN107271696A/zh active Pending
- 2012-03-09 SI SI201230985A patent/SI2760479T1/sl unknown
- 2012-03-09 PT PT128354073T patent/PT2760479T/pt unknown
- 2012-03-09 RS RS20170682A patent/RS56196B1/sr unknown
- 2012-03-09 WO PCT/US2012/028620 patent/WO2013048558A2/en not_active Ceased
- 2012-03-09 HR HRP20171063TT patent/HRP20171063T1/hr unknown
-
2013
- 2013-02-22 US US13/775,000 patent/US9095559B2/en active Active
-
2014
- 2014-03-12 ZA ZA2014/01851A patent/ZA201401851B/en unknown
- 2014-03-27 IL IL231732A patent/IL231732A/en active IP Right Grant
- 2014-03-28 CL CL2014000783A patent/CL2014000783A1/es unknown
- 2014-03-28 MX MX2019006900A patent/MX2019006900A/es unknown
-
2015
- 2015-08-03 US US14/816,674 patent/US9254278B2/en active Active
- 2015-12-03 US US14/958,259 patent/US9326966B2/en active Active
-
2016
- 2016-03-18 US US15/074,691 patent/US20160199333A1/en not_active Abandoned
- 2016-03-18 US US15/074,625 patent/US20160199332A1/en not_active Abandoned
- 2016-03-18 US US15/074,716 patent/US20160199334A1/en not_active Abandoned
- 2016-03-18 US US15/074,666 patent/US20160202240A1/en not_active Abandoned
-
2017
- 2017-01-05 JP JP2017000550A patent/JP6425746B2/ja active Active
- 2017-03-13 US US15/457,643 patent/US9999608B2/en active Active
- 2017-06-28 CY CY20171100688T patent/CY1119028T1/el unknown
- 2017-08-24 IL IL254134A patent/IL254134A0/en unknown
- 2017-08-25 US US15/687,118 patent/US9962358B2/en active Active
- 2017-08-25 US US15/687,132 patent/US9962359B2/en active Active
- 2017-09-08 US US15/699,209 patent/US20180021293A1/en not_active Abandoned
- 2017-10-23 AU AU2017251691A patent/AU2017251691A1/en not_active Abandoned
-
2018
- 2018-04-03 US US15/944,422 patent/US10183003B2/en active Active
- 2018-04-03 US US15/944,432 patent/US10183005B2/en active Active
- 2018-04-03 US US15/944,428 patent/US10183004B2/en active Active
- 2018-04-03 US US15/944,416 patent/US10045959B1/en active Active
- 2018-04-03 US US15/944,411 patent/US10183002B2/en active Active
- 2018-04-03 US US15/944,398 patent/US10045958B1/en active Active
- 2018-05-15 US US15/980,376 patent/US10183006B2/en active Active
- 2018-11-16 US US16/194,061 patent/US10617665B2/en active Active
-
2020
- 2020-03-10 US US16/814,549 patent/US20210000784A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000783A1 (es) | Metodos para determinar si se necesita usar un farmaco depurador de nitrogeno o para determinar el incremento de una dosificacion del farmaco depurador de nitrogeno en un sujeto que recibe actualmente dicho farmaco; y uso del farmaco depurador de nitrogeno para el tratamiento de un trastorno de retencion de nitrogeno, tal como un trastorno del ciclo de urea y encefalopatia hepatica. | |
| GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
| IL227298A0 (en) | Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy | |
| UA117008C2 (uk) | IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ | |
| CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2011003350A1 (es) | Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| UY34651A (es) | ?formas de dosificación de liberación inmediata resistentes a la manipulación, procesos para prepararlas, métodos y usos de las mismas?.. | |
| BR112014006419A2 (pt) | métodos para tratar um paciente com câncer, kit e artigo | |
| ECSP11011258A (es) | Pirimidinas fusionadas | |
| PL2775869T3 (pl) | Wyrób do palenia zawierający mentol | |
| CL2013001009A1 (es) | Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer. | |
| GT201200345A (es) | Compuestos heterocìclicos, su preparaciòn y su aplicaciòn terapèutica | |
| MX2016004741A (es) | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. | |
| CL2013003563A1 (es) | Compuestos derivados de amidas del ácido gambógico y sus sales; composición farmacéutica que los comprende, útil en el tratamiento del glioblastoma. | |
| IL233544B (en) | Compound comprising modified oligonucleotide consisting of 10 to 30 linked nucleosides for use in treating familial dysautonomia | |
| GB2525835A (en) | Composition comprising a diindolymethane and a retinoid to treat a skin condition | |
| MY179576A (en) | Agent for promoting in vivo absorption of hydroxytyrosol and derivatives thereof and use of same | |
| CL2015000056A1 (es) | Compuestos derivados de carbamato/urea, inhibidores del receptor de histamina h3; procedimiento de preparación; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de narcolepsia. | |
| CO6870047A2 (es) | Soporte basado en fibras celulósicas y/o sintéticas, método para producirlo y uso del soporte | |
| AR091888A1 (es) | Compuestos de urea y su uso como inhibidores de enzimas | |
| Agarwal et al. | Asymptotic periodicity for some evolution equations in Banach spaces | |
| BR112014016803A2 (pt) | amidas macrocíclicas como inibidoras de protease | |
| EA201391131A1 (ru) | Сочетания с мацитентаном для лечения полиморфной глиобластомы | |
| CL2013001594A1 (es) | Articulo absorbente que comprende un compuesto de estimulo; un compuesto de estimulo; y metodo para hacer un compuesto de estimulo. | |
| CL2014002430A1 (es) | Uso del compuesto r-p88 (metabolito activo de iloperidona en su forma enantiomerica r) para tratar una enfermedad psiquiatrica tal como esquizofrenia, trastorno bipolar, depresion, autismo, entre otras, cuando se administra una vez al dia; y composicion farmaceutica que comprende el compuesto r-p88. |